Changes to the Code
S. 2658 · Medication Affordability and Patent Integrity Act · Reported The text a committee sent back to its chamber, often with changes, recommending a vote.
Reported by committee · step 2 of 5
21 U.S.C. § 331 Prohibited acts
3 changes the bill asks for here, 1 carried out
- Not carried out:
in clause (B), by striking
; or
and inserting a semicolon;
The bill points to clause (B) of § 331(q)(1), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no clause (B) in /us/usc/t21/s331/q/1 - Not carried out:
in clause (C), by striking the period and inserting
; or
; andThe bill points to clause (C) of § 331(q)(1), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no clause (C) in /us/usc/t21/s331/q/1 - Carried out:
by adding at the end the following:
(D) to submit the certification required under section 505(b)(8)(A)(i) of this Act or section 351(a)(2)(F)(i)(I) of the Public Health Service Act..
§ 331(q)(1)–(3)
Start of § 331 to (q)(1)(A) unchanged ·
(B) to furnish any notification or other material or information required by or under section 360i, 360j(g), 387d, 387i, or 387t of this title; or
(C) to comply with a requirement under section 360l or 387m of this title.
(D) [inserted: to submit the certification required under section 505(b)(8)(A)(i) of this Act or section 351(a)(2)(F)(i)(I) of the Public Health Service Act.]
(2) With respect to any device or tobacco product, the submission of any report that is required by or under this chapter that is false or misleading in any material respect.
(3) The failure to comply with any requirement under section 360n–2(b)(2) of this title (relating to ensuring device cybersecurity).
Rest of § 331 unchanged ·
21 U.S.C. § 355 New drugs
4 changes the bill asks for here, 4 carried out
- Carried out:
Section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is amended by adding at the end the following:
(8) (A) With respect to any application submitted under this subsection or approved under subsection (c), the sponsor of the application or holder of the approved application shall, for any applicable patent— (i) certify to the Food and Drug Administration that the information …
- Carried out:
in clause (vii), by striking
and
at the end; - Carried out:
in clause (viii)(II), by striking the period and inserting
; and
; and - Carried out:
by adding at the end the following:
(ix) with respect to each patent listed in the application pursuant to clause (viii) that is an applicable patent (as defined in paragraph (8)(C)), the certifications required under clauses (i) and (ii)(II) of paragraph (8)(A)..
§ 355(b)Filing application; contents(1)–(2)
Start of § 355 to (b)(1)(A)(v) unchanged ·
(vi) specimens of the labeling proposed to be used for such drug;
(vii) any assessments required under section 355c of this title;[struck: and]
(viii) the patent number and expiration date of each patent for which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug, and that—
(I) claims the drug for which the applicant submitted the application and is a drug substance (active ingredient) patent or a drug product (formulation or composition) patent; or
(II) claims a method of using such drug for which approval is sought or has been granted in the application[struck: .][inserted: ; and]
(ix) [inserted: with respect to each patent listed in the application pursuant to clause (viii) that is an applicable patent (as defined in paragraph (8)(C)), the certifications required under clauses (i) and (ii)(II) of paragraph (8)(A).]
(B) If an application is filed under this subsection for a drug, and a patent of the type described in subparagraph (A)(viii) is issued after the filing date but before approval of the application, the applicant shall amend the application to include the patent number and expiration date.
(2) An application submitted under paragraph (1) for a drug for which the investigations described in clause (A) of such paragraph and relied upon by the applicant for approval of the application were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted shall also include—
§ 355(b)–(c)
(b)(2)(A)–(7)(E) unchanged ·
(i) supersede or modify the authority of the Secretary under section 355h of this title with respect to the regulation of OTC monograph drugs; or
(ii) authorize the disclosure by the Secretary of confidential commercial information or trade secrets.
(8)
(A) [inserted: With respect to any application submitted under this subsection or approved under subsection (c), the sponsor of the application or holder of the approved application shall, for any applicable patent—]
(i) [inserted: certify to the Food and Drug Administration that the information described in subparagraph (B) that is submitted to the Secretary is, to the best knowledge of the sponsor or holder, consistent with the information such sponsor or holder provided to the United States Patent and Trademark Office and any communications such sponsor or holder had with the United States Patent and Trademark Office; and]
(ii)
(I) [inserted: submit to the United States Patent and Trademark Office any information material to patentability, with respect to such applicable patent that the sponsor or holder submits to the Food and Drug Administration, and any information the Food and Drug Administration provided in response; and]
(II) [inserted: certify to the United States Patent and Trademark Office that the submission under subclause (I), to the best knowledge of the sponsor or holder, includes all information material to patentability and is consistent with the information such sponsor or holder provided to the Food and Drug Administration and any communications such sponsor or holder had with the Food and Drug Administration.]
(B) [inserted: The information described in this subparagraph is limited to information that is material to patentability, as defined in regulations promulgated by the United States Patent and Trademark Office, and that is—]
(i) [inserted: any statement or characterization of analytical data set forth in the chemistry, manufacturing, and controls section of a new drug application disclosed by the sponsor of the application or holder of the approved application under this section to the United States Patent and Trademark Office that has been, or will be, submitted to the Food and Drug Administration to support the approval of an application under this section;]
(ii) [inserted: any statement or characterization with respect to an applicable patent, including any statement or characterization of prior art, submitted by the sponsor of the application or holder of the approved application to the United States Patent and Trademark Office in support of patentability; or]
(iii) [inserted: other information, as the Secretary or the Secretary of Commerce may by regulation require.]
(C) [inserted: In this paragraph, the term “applicable patent” means—]
(i) [inserted: a patent that—]
(I) [inserted: claims a drug that is the subject of an application described in subparagraph (A), including any patent that claims, with respect to such a drug, a formulation or composition, method of use, or method of manufacturing; and]
(II) [inserted: is issued, assigned, or exclusively licensed to the sponsor of the application or holder of the approved application described in subparagraph (A);]
(ii) [inserted: an application for a patent described in clause (i)(I) that is sought by the sponsor of the application or holder of the approved application described in subparagraph (A); or]
(iii) [inserted: such other patent or application for a patent as the Secretary or the Secretary of Commerce may by regulation require.]
(D)
(i) [inserted: Except as provided in clause (ii), subparagraph (A) shall apply with respect to any original application submitted under this subsection on or after the date of enactment of the Medication Affordability and Patent Integrity Act and to any amendments or supplements to such original application.]
(ii) [inserted: In the case of an application submitted under this subsection before the date of enactment of the Medication Affordability and Patent Integrity Act, the requirements of subparagraph (A) apply only with respect to—]
(I) [inserted: any applicable patent issued on or after such date of enactment; and]
(II) [inserted: in the case of an applicable patent issued before such date of enactment, only to submissions and communications described in clauses (i) and (ii) of subparagraph (A) made on or after such date of enactment.]
(E)
(i) [inserted: Any information that the sponsor of the application or holder of the approved application has submitted to or received from the Food and Drug Administration that is submitted to the United States Patent and Trademark Office to fulfill the requirements of subparagraph (A), and that would not otherwise be submitted to the United States Patent and Trademark Office, shall remain subject to protections for trade secret or confidential information or financial information applicable to such application as if the information were held by the Food and Drug Administration, except that such protections shall not apply to information that the United States Patent and Trademark Office determines necessary for the public to understand the scope of patent claims granted.]
(ii) [inserted: The United States Patent and Trademark Office shall, as necessary, update its applicable regulations or establish new procedures to ensure compliance with clause (i) for information submitted under this paragraph.]
(c) Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order
(1) Within one hundred and eighty days after the filing of an application under subsection (b), or such additional period as may be agreed upon by the Secretary and the applicant, the Secretary shall either—
Rest of § 355 unchanged ·
35 U.S.C. § 274 Non-disclosure defense to infringement of drug patent New section
1 change the bill asks for here, 1 carried out
- Carried out:
Chapter 28 of title 35, United States Code, is amended by adding at the end the following:274. Non-disclosure defense to infringement of drug patent A person shall be entitled to a defense under section 282(b) in an action asserting infringement of an applicable patent (as defined in paragraph (8)(C) of section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) or subparagraph (F)(iii) of section 351(a)(2) of the Public Health Service Act (42 U.S.C. 262(a)(2))) if the owner or predecessor owner of the applicable patent violated paragraph (8)(A) of such section 505(b) or subparagraph (F)(i) of such section 351(a)(2) with respect to the applicable patent by negligently or intentionally failing to disclose any information required to be disclosed pursuant to such paragraph (8)(A) or such subparagraph (F)(i), on the condition that such a defense shall not be available if the person asserting such a defense is a covered foreign person (as defined in section 809 of the Defense Production Act of 1950 (50 U.S.C. 4589))..
§ 274(1)
§ 274. [inserted: Non-disclosure defense to infringement of drug patent]
[inserted: A person shall be entitled to a defense under section 282(b) in an action asserting infringement of an applicable patent (as defined in paragraph (8)(C) of section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) or subparagraph (F)(iii) of section 351(a)(2) of the Public Health Service Act (42 U.S.C. 262(a)(2))) if the owner or predecessor owner of the applicable patent violated paragraph (8)(A) of such section 505(b) or subparagraph (F)(i) of such section 351(a)(2) with respect to the applicable patent by negligently or intentionally failing to disclose any information required to be disclosed pursuant to such paragraph (8)(A) or such subparagraph (F)(i), on the condition that such a defense shall not be available if the person asserting such a defense is a covered foreign person (as defined in section 809 of the Defense Production Act of 1950 (50 U.S.C. 4589)).]
42 U.S.C. § 262 Regulation of biological products
1 change the bill asks for here, 1 carried out
- Carried out:
Section 351(a)(2) of the Public Health Service Act (42 U.S.C. 262(a)(2)) is amended by adding at the end the following:
(F) (i) With respect to any application submitted under this subsection or biological product licensed under this subsection, the sponsor of the application or holder of the license shall, for any applicable patent— (I) certify to the Food and Drug Administration that the …
§ 262(a)–(b)
Start of § 262 to (a)(2)(E) unchanged ·
(i) The Secretary may rely upon qualified data summaries to support the approval of a supplemental application, with respect to a qualified indication for a drug, submitted under this subsection, if such supplemental application complies with the requirements of subparagraph (B) of section 505(c)(5) of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355(c)(5)].
(ii) In this subparagraph, the terms “qualified indication” and “qualified data summary” have the meanings given such terms in section 505(c)(5) of the Federal Food, Drug, and Cosmetic Act.
(F)
(i) [inserted: With respect to any application submitted under this subsection or biological product licensed under this subsection, the sponsor of the application or holder of the license shall, for any applicable patent—]
(I) [inserted: certify to the Food and Drug Administration that the information described in clause (ii) that is submitted to the Secretary is, to the best knowledge of the sponsor or holder, consistent with the information such sponsor or holder provided to the United States Patent and Trademark Office and any communications such sponsor or holder had with the United States Patent and Trademark Office; and]
(II)
(aa) [inserted: submit to the United States Patent and Trademark Office any information material to patentability with respect to such applicable patent that the sponsor or holder submits to the Food and Drug Administration, and any information the Food and Drug Administration provided in response; and]
(bb) [inserted: certify to the United States Patent and Trademark Office that the submission under item (aa), to the best knowledge of the sponsor or holder, includes all information material to patentability and is consistent with the information such sponsor or holder provided to the Food and Drug Administration and any communications such sponsor or holder had with the Food and Drug Administration.]
(ii) [inserted: The information described in this clause is limited to information that is material to patentability, as defined in regulations promulgated by the United States Patent and Trademark Office, and that is—]
(I) [inserted: any statement or characterization of analytical data set forth in the chemistry, manufacturing, and controls section of a biological product license application disclosed by the sponsor of the application or holder of the approved application under this section to the United States Patent and Trademark Office that has been, or will be, submitted to the Food and Drug Administration to support the approval of an application under this section;]
(II) [inserted: any statement or characterization with respect to an applicable patent, including any statement or characterization of prior art, submitted by the sponsor of the application or holder of the approved application to the United States Patent and Trademark Office in support of patentability; or]
(III) [inserted: other information, as the Secretary or the Secretary of Commerce may by regulation require.]
(iii) [inserted: In this subparagraph, the term “applicable patent” means—]
(I) [inserted: a patent that—]
(aa) [inserted: claims a biological product that is the subject of an application described in clause (i), including any patent that claims, with respect to such biological product, a formulation or composition, method of use, or method of manufacturing; and]
(bb) [inserted: is issued, assigned, or exclusively licensed to the sponsor of the application or holder of the license described in clause (i);]
(II) [inserted: an application for a patent described in subclause (I)(aa) that is sought by the sponsor of the application or holder of the license described in clause (i); or]
(III) [inserted: such other patent or application for a patent as the Secretary or Secretary of Commerce may by regulation require.]
(iv)
(I) [inserted: Except as provided in subclause (II), clause (i) shall apply with respect to any original application submitted under this subsection on or after the date of enactment of the Medication Affordability and Patent Integrity Act and to any amendments or supplements to such original application.]
(II) [inserted: In the case of an application submitted under this subsection before the date of enactment of the Medication Affordability and Patent Integrity Act, the requirements of clause (i) apply only with respect to—]
(aa) [inserted: any applicable patent issued on or after such date of enactment; and]
(bb) [inserted: in the case of an applicable patent issued before such date of enactment, only to submissions and communications described in subclauses (I) and (II) of clause (i) made on or after such date of enactment.]
(v)
(I) [inserted: Any information that the sponsor of the application or holder of the license has submitted to or received from the Food and Drug Administration that is submitted to the United States Patent and Trademark Office to fulfill the requirements of clause (i), and that would not otherwise be submitted to the United States Patent and Trademark Office, shall remain subject to protections for trade secret or confidential information or financial information applicable to such application or license as if the information were held by the Food and Drug Administration, except that such protections shall not apply to information that the United States Patent and Trademark Office determines necessary for the public to understand the scope of patent claims granted.]
(II) [inserted: The United States Patent and Trademark Office shall, as necessary, update its applicable regulations or establish new procedures to ensure compliance with subclause (I) for information submitted under this subparagraph.]
(3) The Secretary shall prescribe requirements under which a biological product undergoing investigation shall be exempt from the requirements of paragraph (1).
(b) Falsely labeling or marking package or container; altering label or mark No person shall falsely label or mark any package or container of any biological product or alter any label or mark on the package or container of the biological product so as to falsify the label or mark.
Rest of § 262 unchanged ·